Nephros 10Q 2019 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended:September 30, 2019

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _______ to _______

Commission File Number: 001-32288

NEPHROS, INC.

(Exact name of registrant as specified in its charter)

Delaware		13-3971809
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

380 Lackawanna Place South Orange, NJ		07079
(Address of principal executive offices)		(Zip Code)

(201) 343-5202

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of exchange on which registered
Common stock, par value $0.001 per share		NEPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] YES [ ] NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] YES [ ] NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [X]	Smaller reporting company [X]
	Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] YES [X] NO

As of November 1, 2019, 7,963,412 shares of the registrant’s common stock, $0.001 par value per share, were outstanding.

NEPHROS, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION	3
Item 1. Financial Statements (unaudited)	3
CONDENSED CONSOLIDATED BALANCE SHEETS – September 30, 2019 and December 31, 2018	3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS – Three and nine months ended September 30, 2019 and 2018	4
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY – Three and nine months ended September 30, 2019 and 2018	5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – Nine months ended September 30, 2019 and 2018	7
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	25
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	36
Item 4. Controls and Procedures.	36
PART II - OTHER INFORMATION	37
Item 6. Exhibits	37
SIGNATURES	38

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

NEPHROS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

	September 30, 2019			December 31, 2018
ASSETS
Current assets:
Cash	$	3,855		$	4,581
Accounts receivable, net		1,894			1,452
Inventory, net		2,128			1,864
Prepaid expenses and other current assets		240			276
Total current assets		8,117			8,173
Property and equipment, net		85			91
Operating lease right-of-use assets		1,165			-
Intangible assets, net		559			590
Goodwill		759			748
License and supply agreement, net		837			938
Other assets		32			18
TOTAL ASSETS	$	11,554		$	10,558

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Secured revolving credit facility	$	982		$	991
Current portion of secured note payable		207			195
Accounts payable		690			836
Accrued expenses		715			396
Current portion of contingent consideration		271			236
Current portion of operating lease liabilities		251			-
Total current liabilities		3,116			2,654
Secured note payable, net of current portion		672			843
Equipment financing debt, net of current portion		10			-
Contingent consideration, net of current portion		78			263
Operating lease liabilities, net of current portion		956			-
TOTAL LIABILITIES		4,832			3,760

COMMITMENTS AND CONTINGENCIES (Note 16)

STOCKHOLDERS’ EQUITY

Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2019 and December 31, 2018; no shares issued and outstanding at September 30, 2019 and December 31, 2018.		-			-
Common stock, $.001 par value; 40,000,000 and 10,000,000 shares authorized at September 30, 2019 and December 31, 2018, respectively; 7,784,535 and 7,179,514 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively.		8			7
Additional paid-in capital		130,830			127,873
Accumulated other comprehensive income		63			71
Accumulated deficit		(127,188	)		(124,153	)
Subtotal		3,713			3,798
Noncontrolling interest		3,009			3,000
TOTAL STOCKHOLDERS’ EQUITY		6,722			6,798
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	11,554		$	10,558

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Net revenues:
Product revenues	$	3,054		$	1,648		$	7,067		$	3,822
Royalty and other revenues		41			76			106			253
Total net revenues		3,095			1,724			7,173			4,075
Cost of goods sold		1,276			772			2,989			1,826
Gross margin		1,819			952			4,184			2,249
Operating expenses:
Research and development		777			352			2,326			993
Depreciation and amortization		44			42			142			123
Selling, general and administrative		1,787			1,069			4,693			3,420
Change in fair value of contingent consideration		(94	)		-			(113	)		-
Total operating expenses		2,514			1,463			7,048			4,536
Loss from operations		(695	)		(511	)		(2,864	)		(2,287	)
Other income (expense):
Loss on extinguishment of debt		-			-			-			(199	)
Interest expense		(48	)		(32	)		(140	)		(146	)
Interest income		-			1			-			3
Other expense, net		(1	)		(8	)		(31	)		(32	)
Net loss		(744	)		(550	)		(3,035	)		(2,661	)
Less: Undeclared deemed dividend attributable to noncontrolling interest		(60	)		(16	)		(180	)		(16	)
Net loss attributable to Nephros, Inc. shareholders	$	(804	)	$	(566	)	$	(3,215	)	$	(2,677	)

Net loss per common share, basic and diluted	$	(0.10	)	$	(0.08	)	$	(0.43	)	$	(0.40	)
Weighted average common shares outstanding, basic and diluted		7,703,033			7,129,617			7,408,569			6,751,317

Comprehensive loss:
Net loss	$	(744	)	$	(550	)	$	(3,035	)	$	(2,661	)
Other comprehensive loss, foreign currency translation adjustments, net of tax		(7	)		(1	)		(8	)		(4	)
Comprehensive loss		(751	)		(551	)		(3,043	)		(2,665	)
Comprehensive loss attributable to noncontrolling interest		(60	)		(16	)		(180	)		(16	)
Comprehensive loss attributable to Nephros, Inc. shareholders	$	(811	)	$	(567	)	$	(3,223	)	$	(2,681	)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(In thousands, except share amounts)

(Unaudited)

	Three and nine months ended September 30, 2019
	Common Stock					Additional Paid-in		Accumulated Other Comprehensive			Accumulated						Noncontrolling		Total Stockholders’
	Shares			Amount		Capital		Income			Deficit			Subtotal			Interest		Equity
Balance, December 31, 2018		7,134,719		$	7	$	127,873	$	71		$	(124,153	)	$	3,798		$	3,000	$	6,798
Net loss												(1,349	)		(1,349	)				(1,349	)
Net unrealized losses on foreign currency translation, net of tax									(3	)					(3	)				(3	)
Noncash stock-based compensation							158								158					158
Balance, March 31, 2019		7,134,719		$	7	$	128,031	$	68		$	(125,502	)	$	2,604		$	3,000	$	5,604
Net loss												(942	)		(942	)				(942	)
Net unrealized gains on foreign currency translation, net of tax									2						2					2
Issuance of common stock, net of equity issuance costs of $8		493,827			1		1,991								1,992					1,992
Issuance of vested restricted stock		44,270			-
Noncash stock-based compensation							147								147			3		150
Balance, June 30, 2019		7,672,816		$	8	$	130,169	$	70		$	(126,444	)	$	3,803		$	3,003	$	6,806
Net loss												(744	)		(744	)				(744	)
Net unrealized losses on foreign currency translation, net of tax									(7	)					(7	)				(7	)
Exercise of warrants		108,147			-		292								292					292
Exercise of stock options		4,166			-		21								21					21
Aggregate fractional shares cancelled due to reverse stock split		(594	)		-										-					-
Noncash stock-based compensation							348								348			6		354
Balance, September 30, 2019		7,784,535		$	8	$	130,830	$	63		$	(127,188	)	$	3,713		$	3,009	$	6,722

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(In thousands, except share amounts)

(Unaudited)

	Three and nine months ended September 30, 2018
	Common Stock				Additional Paid-in		Accumulated Other Comprehensive			Accumulated						Noncontrolling		Total Stockholders’
	Shares		Amount		Capital		Income			Deficit			Subtotal			Interest		Equity
Balance, December 31, 2017		6,143,663	$	6	$	122,973	$	77		$	(121,106	)	$	1,950		$	-	$	1,950
Net loss											(1,429	)		(1,429	)				(1,429	)
Cumulative effect of adoption of ASC 606											278			278					278
Net unrealized gains on foreign currency translation, net of tax								3						3					3
Issuance of common stock		211,111		-		854								854					854
Cashless exercise of stock options		2.471		-										-					-
Noncash stock-based compensation						242								242					242
Balance, March 31, 2018		6,357,245	$	6	$	124,069	$	80		$	(122,257	)		1,898		$	-	$	1,898
Net loss											(682	)		(682	)				(682	)
Net unrealized losses on foreign currency translation, net of tax								(6	)					(6	)				(6	)
Issuance of common stock, net of equity issuance costs of $19		726,735		1		2,923								2,924					2,924
Exercise of warrants		50,739		-		138								138					138
Noncash stock-based compensation						226								226					226
Balance, June 30, 2018		7,134,719	$	7	$	127,356	$	74		$	(122,939	)	$	4,498		$	-	$	4,498
Net loss											(550	)		(550	)				(550	)
Net unrealized losses on foreign currency								(1	)					(1	)				(1	)
Noncash stock-based compensation						120								120					120
Balance, September 30, 2018		7,134,719	$	7	$	127,476	$	73		$	(123,489	)	$	4,067		$	-	$	4,067

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, except share amounts)

(Unaudited)

	Nine Months Ended September 30,
	2019			2018
OPERATING ACTIVITIES:
Net loss	$	(3,035	)	$	(2,661	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment		20			22
Amortization of intangible assets and license and supply agreement		132			101
Non-cash stock-based compensation, including stock options and restricted stock		662			588
Loss on extinguishment of debt		-			199
Amortization of debt discount		-			34
Inventory reserve		37			65
Allowance for doubtful accounts reserve		19			21
Change in fair value of contingent consideration		(113	)		-
Accretion of contingent consideration		41			-
Loss on disposal of equipment		-			10
Gain on foreign currency transactions		(2	)		(1	)
(Increase) decrease in operating assets:
Accounts receivable		(461	)		(684	)
Inventory		(301	)		(850	)
Prepaid expenses and other current assets		21			22
Operating right-of-use assets and operating lease liabilities		49			-
Other assets		(21	)		-
Increase (decrease) in operating liabilities:
Accounts payable		(144	)		(309	)
Accrued expenses		456			309
Net cash used in operating activities		(2,640	)		(3,134	)
INVESTING ACTIVITIES:
Purchase of equipment		(14	)		-
Acquisition of Biocon		(137	)		-
Net cash used in investing activities		(151	)		-
FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of equity issuance costs of $8 and $19, respectively		1,992			3,778
Net payments on secured revolving credit facility		(9	)		(548	)
Proceeds from sale of subsidiary preferred shares to noncontrolling interest		-			3,000
Proceeds from equipment financing		14			-
Principal payments on equipment financing debt		(1	)		-
Payments on secured note payable		(159	)		(99	)
Proceeds from exercise of warrants		292			138
Proceeds from exercise of stock options		21			-
Payment of contingent consideration		(78	)		-
Proceeds from issuance of secured note		-			1,187
Repayment of unsecured long term note payable		-			(1,187	)
Net cash provided by financing activities		2,072			6,269
Effect of exchange rates on cash		(7	)		(7	)
Net (decrease) increase in cash		(726	)		3,128
Cash, beginning of period		4,581			2,194
Cash, end of period	$	3,855		$	5,322
Supplemental disclosure of cash flow information
Cash paid for interest	$	98		$	124
Cash paid for income taxes	$	4		$	7
Supplemental disclosure of noncash investing and financing information
Right-of-use asset obtained in exchange for lease liability	$	800		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

NEPHROS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

Note 1 – Organization and Nature of Operations

Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. The Company was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced end stage renal disease (“ESRD”) therapy technology and products.

Beginning in 2009, Nephros introduced high performance liquid purification filters to meet the demand for water purification in certain medical markets. The Company’s filters, generally classified as ultrafilters, are primarily used in hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. The Company also develops and sells water filtration products for commercial applications, focusing on the hospitality and food service markets. The Company is also exploring water purification applications in other markets, including diagnostics, military field applications, and data center cooling. The water filtration business is a reportable segment, referred to as the Water Filtration segment.

In July 2018, the Company formed a new, wholly-owned subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of its second-generation hemodiafiltration (“HDF”) system and other products focused on improving therapies for patients with renal disease. The Company transferred three patents to SRP, which were carried at zero book value. SRP is a reportable segment, referred to as the Renal Products segment.

On December 31, 2018, the Company entered into a Membership Interest Purchase Agreement (the “Biocon Agreement”) with Biocon 1, LLC, a Nevada limited liability company (“Biocon”), Aether Water Systems, LLC, a Nevada limited liability company (“Aether”), and Gregory Lucas, the sole member of each of Biocon and Aether. Pursuant to the terms of the Biocon Agreement, the Company acquired 100% of the outstanding membership interests of each of Aether and Biocon (the “Biocon Acquisition”).

The Company’s primary U.S. facilities are located at 380 Lackawanna Place, South Orange, New Jersey, 07079, and at 3221 Polaris Avenue, Las Vegas, Nevada 89102. These locations house the Company’s corporate headquarters, research, manufacturing, and distribution facilities. In addition, the Company maintains small administrative offices in various locations in the U.S. and Ireland.

Note 2 – Basis of Presentation and Liquidity

Interim Financial Information

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 and Article 10 of Regulation S-X. The condensed consolidated balance sheet at December 31, 2018 was derived from the Company’s audited annual financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. Results as of and for the nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

The condensed consolidated interim financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Reverse Stock Split

On May 22, 2019, the Company’s Board of Directors authorized a 1-for-9 reverse stock split and approved an amendment to the Company’s Certificate of Incorporation to affect the 1-for-9 reverse split of the Company’s common stock, which was effected at 5:30 p.m. ET on July 9, 2019. Fractional shares were not issued and stockholders who otherwise would have been entitled to receive a fractional share as a result of the reverse stock split received an amount in cash equal to $5.58 per share for such fractional interests. All of the share and per share amounts discussed in the accompanying condensed consolidated financial statements have been adjusted to reflect the effect of this reverse split.

Consolidation

The accompanying condensed consolidated financial statements include the accounts of Nephros, Inc. and its subsidiaries, including SRP, in which a controlling interest is maintained by the Company. Outside shareholders’ interest in SRP of 37.5% is shown on the condensed consolidated balance sheet as noncontrolling interest. All intercompany accounts and transactions were eliminated in the preparation of the accompanying condensed consolidated financial statements.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets, value of contingent consideration, the assessment of the ability to continue as a going concern and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.

Liquidity

The Company has sustained operating losses and expects such losses to continue over the next several quarters. In addition, net cash from operations has been negative since inception, generating an accumulated deficit of approximately $127,188,000 as of September 30, 2019. Also, the Company has a loan agreement with a lender, which provides a secured asset-based revolving credit facility of up to $1,000,000. This loan agreement automatically renewed on August 17, 2019.

On May 15, 2019, the Company completed a private placement transaction whereby the Company sold 493,827 shares of its common stock for aggregate net proceeds of approximately $1,992,000.

In July 2018, the Company formed a new, wholly-owned subsidiary, SRP, to drive the development of its second-generation HDF system and other products focused on improving therapies for patients with renal disease. On September 5, 2018, SRP completed a private placement transaction whereby SRP sold preferred shares equivalent to 37.5% of its outstanding equity interests for aggregate proceeds of $3,000,000. The proceeds of this private placement are restricted to SRP expenses and may not be used for the benefit of the Company or other affiliated entities, except to reimburse for expenses directly attributable to SRP.

Based on cash that is available for Company operations and projections of future Company operations, the Company believes that its cash will be sufficient to fund the Company’s current operating plan through at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. In the event that operations do not meet expectations, the Company will reduce discretionary expenditures such as additional headcount, new R&D projects, and other variable costs to alleviate the substantial doubt as to the Company’s ability to continue as a going concern. The Company may also seek to raise additional capital, however, there can be no assurance that any such actions could be affected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases,” (“ASC 842”) which discusses how an entity should account for lease assets and lease liabilities. The guidance specifies that an entity who is a lessee under lease agreements should recognize lease assets and lease liabilities for those leases classified as operating leases under previous FASB guidance. The Company adopted the guidance on January 1, 2019 using the transition method provided by ASU 2018-11, “Leases (Topic 842): Targeted Improvements”. Under this transition method, the Company applied the new requirements to only those leases that existed as of January 1, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods will be presented under existing lease guidance. Upon transition, the Company applied the package of practical expedients permitted under the ASC 842 transition guidance. As a result, the Company did not reassess (1) whether expired or existing contracts contain leases under the new definition of a lease, including whether an existing or expired contract contains an embedded lease, (2) lease classification for expired or existing leases and (3) any initial direct costs of existing leases. As a result of the adoption of this guidance on January 1, 2019, the Company recorded right-of-use assets of approximately $613,000, net of approximately $8,000 of deferred rent liability, and lease liabilities of approximately $621,000. Adoption of the guidance did not have any impact on the Company’s consolidated statements of operations and comprehensive loss or cash provided by or used in operating, investing or financing activities on its consolidated statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted beginning in the first quarter of fiscal year 2019. The Company early adopted this guidance as of January 1, 2019 and the guidance did not have an impact on its consolidated financial statements.

In May 2018, the FASB issued ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting,” which expands the scope of Accounting Standards Codification (“ASC”) 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this guidance as of January 1, 2019 and the guidance did not have an impact on its consolidated financial statements.

Recent Accounting Pronouncements, Not Yet Effective

In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment,” which simplifies the test for goodwill impairment. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted for interim or annual goodwill impairments tests after January 1, 2017. The Company is assessing the impact of adopting this guidance on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework-Changes to the Disclosure Requirements for the Fair Value Measurement,” which modifies the disclosure requirements on fair value measurements. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is assessing the impact of adopting this guidance on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract,” which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is assessing the impact of adopting this guidance on its consolidated financial statements.

In November 2018, the FASB issued ASU 2018-18, “Collaborative Arrangements: Clarifying the Interaction Between Topic 808 and Topic 606.” This guidance clarifies that, when the collaborative arrangement participant is a customer in the context of a unit-of-account, revenue from contracts with customers guidance should be applied, adds unit-of-account guidance to collaborative arrangements guidance, and requires, that in a transaction with a collaborative arrangement participant who is not a customer, presenting the transaction together with revenue recognized under contracts with customers is precluded. The guidance is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is assessing the impact of adopting this guidance on its consolidated financial statements.

Concentration of Credit Risk

The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash. The Company also limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary.

Major Customers

For the three months ended September 30, 2019 and 2018, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2019			2018
A		31	%		10	%
B		19	%		7	%
C		7	%		13	%
D		-	%		13	%
E		4	%		10	%
F		6	%		10	%
Total		67	%		63	%

For the nine months ended September 30, 2019 and 2018, the following customers accounted for the following percentages of the Company’s revenues, respectively:

Customer	2019			2018
A		18	%		12	%
B		17	%		5	%
C		10	%		8	%
E		5	%		12	%
Total		50	%		37	%

As of September 30, 2019 and December 31, 2018, the following customers accounted for the following percentages of the Company’s accounts receivable, respectively:

Customer	2019			2018
A		33	%		1	%
B		21	%		5	%
G		-	%		15	%
E		5	%		11	%
C		2	%		11	%
Total		61	%		43	%

Accounts Receivable

The Company provides credit terms to customers in connection with purchases of the Company’s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer’s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management’s best estimate of potential losses. The allowance for doubtful accounts was approximately $29,000 and $15,000 as of September 30, 2019 and December 31, 2018, respectively. For the three and nine months ended September 30, 2019, the provision for bad debt expense was approximately $19,000. Write-offs of accounts receivable were approximately $5,000 for the nine months ended September 30, 2019 which were reserved for in a prior period. There were no write-offs of accounts receivable for the three months ended September 30, 2019. There was no allowance for sales returns at September 30, 2019 or December 31, 2018. During the three and nine months ended September 30, 2018, there was no provision for bad debt expense and there were no write-offs of accounts receivable.

Depreciation Expense

Depreciation related to equipment utilized in the manufacturing process is recognized in cost of goods sold on the condensed consolidated statements of operations and comprehensive loss. For the three months ended September 30, 2019 and 2018, depreciation expense was approximately $4,000 and $8,000, respectively. For the nine months ended September 30, 2019 and 2018, depreciation expense was approximately $20,000 and $22,000, respectively. Approximately $4,000 and $10,000 of depreciation expense has been recognized in cost of goods sold for the three and nine months ended September 30, 2019, respectively. There was no depreciation recognized in cost of goods sold for the three or nine months ended September 30, 2018.

Leases

The Company determines if an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities on the condensed consolidated balance sheet.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company has elected, as an accounting policy not to apply the recognition requirements in ASC 842 to short-term leases. Short-term leases are leases that have a term of 12 months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease payments for short-term leases on a straight-line basis over the lease term.

The Company has also elected, as a practical expedient, by underlying class of asset, not to separate lease components from nonlease components and, instead, account for them as a single component.

Note 3 – Biocon Acquisition

On December 31, 2018, the Company completed the Biocon Acquisition, which included the acquisition of 100% of the outstanding membership interests of each of Aether and Biocon. The purpose of the Biocon Acquisition was to accelerate growth and to expedite entry into additional markets.

Transaction costs associated with the Biocon Acquisition of approximately $33,000 were recorded in selling, general and administrative costs for the year ended December 31, 2018.

The Company has accounted for the Biocon Acquisition as a business combination under the acquisition method of accounting.

The following is a summary of total consideration for the Biocon Acquisition, including a final working capital adjustment in the nine months ended September 30, 2019 of approximately $11,000:

	Total Consideration

Fixed purchase price	$	1,070,000
Acquisition date fair value of contingent consideration		562,000
Total consideration¹	$	1,632,000

¹Total consideration of $1,632,000 consists of $5,000 in accrued expenses, $137,000 in working capital payments, $499,000 of contingent consideration liabilities, and an upfront payment of $991,000, of which $250,000 is held in escrow.

The Company has allocated the total consideration for the transaction based upon the fair value of net assets acquired and liabilities assumed at the date of acquisition.

The following is a summary of the final purchase price allocation for the Biocon Acquisition. Changes to the purchase price allocation from amounts reported on the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 were due to the final working capital adjustment.

	Fair Values
Trade accounts receivable	$	164,000
Inventories		179,000
Equipment		39,000
Security deposit		7,000
Goodwill		759,000
Intangible assets		590,000
Total assets acquired, net of cash acquired		1,738,000
Accounts payable		91,000
Accrued expenses		15,000
Total liabilities assumed		106,000
Net assets acquired, net of cash acquired	$	1,632,000

Intangible Assets

The acquired intangible assets are being amortized over their estimated useful lives as follows:

	Fair Values		Weighted Average Useful Life (Years)
Tradenames, service marks and domain names		50,000		5
Customer relationships		540,000		17
Total intangible assets	$	590,000

The estimated fair value of the identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The assumptions, including the expected projected cash flows, utilized in the purchase price allocation and in determining the purchase price were based on the Company’s best estimates as of December 31, 2018, the closing date of the Biocon Acquisition.

Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of goods sold, research and development costs, selling and marketing costs and working capital / contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream, as well as other factors. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.

Goodwill

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized. Factors that contributed to the Company’s recognition of goodwill include the Company’s intent to expand its product portfolio. Goodwill has been allocated to the Water Filtration segment.

Unaudited Pro Forma Results of Operations

The following table reflects the unaudited pro forma combined results of operations for the three and nine months ended September 30, 2018 (assuming the closing of the Biocon Acquisition occurred on January 1, 2017):

	Three Months Ended			Nine Months Ended
	September 30, 2018			September 30, 2018
Total revenues	$	1,906,000		$	4,578,000
Net loss attributable to Nephros, Inc	$	(510,000	)	$	(2,573,000	)

The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the closing of the Biocon Acquisition taken place on January 1, 2017. Furthermore, the pro forma results do not purport to project the future results of operations of the Company.

The unaudited pro forma information reflects the following adjustments:

●

Adjustments to amortization expense for the three and nine months ended September 30, 2018 of approximately $10,000 and $31,000, respectively related to identifiable intangible assets acquired;

●

Eliminate interest expense in the historical Biocon results of operations and eliminate interest income in the Company’s historical results of operations, each of which was approximately $1,000 and $3,000 for the three and nine months ended September 30, 2018, respectively, which interest was related to a lease that was terminated as of the acquisition; and

●

Eliminate sales, and related cost of goods, for products sold by Biocon to the Company, with a gross margin impact of approximately $1,000 and $3,000 for the three and nine months ended September 30, 2018, respectively.

Note 4 – Revenue Recognition

The Company recognizes revenue related to product sales when product is shipped via external logistics provider and the other criteria of ASC 606, “Revenue from Contracts with Customers,” (“ASC 606”) are met. Product revenue is recorded net of returns and allowances. In addition to product revenue, the Company recognizes revenue related to royalty and other agreements in accordance with the five-step model in ASC 606. Royalty and other revenue recognized for the three and nine months ended September 30, 2019 and 2018 is comprised of:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Royalty revenue under the Sublicense Agreement with CamelBak⁽¹⁾	$	-	$	-	$	-	$	100,000
Royalty revenue under the License Agreement with Bellco		10,000		21,000		50,000		79,000
Other revenue		31,000		55,000		56,000		74,000
Total royalty and other revenue	$	41,000	$	76,000	$	106,000	$	253,000

(1)

In May 2015, the Company entered into a Sublicense Agreement with CamelBak Products, LLC (“CamelBak”). Under the Sublicense Agreement, the Company granted CamelBak an exclusive, non-transferable, worldwide (with the exception of Italy) sublicense and license, in each case solely to market, sell, distribute, import and export the Company’s individual water treatment device. In exchange for the rights granted to CamelBak, CamelBak agreed, through December 31, 2022, to pay the Company a percentage of the gross profit on any sales made to a branch of the U.S. military, subject to certain exceptions, and to pay a fixed per-unit fee for any other sales made. CamelBak was also required to meet or exceed certain minimum annual fees payable to the Company, and if such fees are not met or exceeded, the Company may convert the exclusive sublicense to a non-exclusive sublicense with respect to non-U.S. military sales. In the first quarter of 2019, the Sublicense Agreement was amended to eliminate the minimum fee obligations starting May 6, 2018 and, as such, Camelbak has no further minimum fee obligations.

Bellco License Agreement

With regard to the OLpūr MD190 and MD220, on June 27, 2011, the Company entered into a License Agreement (the “License Agreement”), effective July 1, 2011, with Bellco S.r.l. (“Bellco”), an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of the Company’s patented mid-dilution dialysis filters (the “Products”). Under the License Agreement, as amended, the Company granted Bellco a license to manufacture, market and sell the Products under its own name, label, and CE mark in certain countries on an exclusive basis, and to do the same on a non-exclusive basis in certain other countries. Under the License Agreement with Bellco, the Company received upfront payments which were previously deferred and recognized as license revenue over the term of the License Agreement. As of the adoption of ASC 606, the remaining deferred revenue of approximately $278,000 was recognized as a cumulative effect adjusted to accumulated deficit as of January 1, 2018 in accordance with ASC 606.

The License Agreement, as amended, also provides minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. Beginning on January 1, 2015 through and including December 31, 2021, Bellco will pay the Company a royalty based on the number of units of Products sold per year in the covered territory as follows: for the first 125,000 units sold in total, €1.75 (approximately $1.95) per unit; thereafter, €1.25 (approximately $1.40) per unit. The License Agreement also provides for a fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021 if the minimum sales targets are not met.

The Company recognized royalty income from Bellco pursuant to the License Agreement for the three months ended September 30, 2019 and 2018 of approximately $10,000 and $21,000, respectively. The Company recognized royalty income from Bellco pursuant to the License Agreement for the nine months ended September 30, 2019 and 2018 of approximately $50,000 and $79,000, respectively.

Note 5 – Fair Value Measurements

The Company measures certain financial instruments and other items at fair value.

To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability.

To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period.

The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of September 30, 2019:

Quoted prices in

active markets

for

identical assets

(Level 1)

Significant other

observable

inputs

(Level 2)

Significant

unobservable

inputs

(Level 3)

Total

At September 30, 2019:

Total contingent consideration liability

349,000

The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of December 31, 2018:

Quoted prices in

active markets

for

identical assets

(Level 1)

Significant other

observable

inputs

(Level 2)

Significant

unobservable

inputs

(Level 3)

Total

At December 31, 2018:

Total contingent consideration liability

499,000

The following table summarizes the change in fair value, as determined by Level 3 inputs, for the contingent consideration liability using unobservable Level 3 inputs for the nine months ended September 30, 2019:

	Contingent Consideration
Balance as of December 31, 2018	$	499,000
Payments against contingent consideration		(78,000	)
Change in fair value of contingent consideration liability		(113,000	)
Accretion of contingent consideration liability		41,000
Balance as of September 30, 2019	$	349,000

Consideration paid in a business combination may include potential future payments that are contingent upon the acquired business achieving certain levels of earnings in the future (“contingent consideration”). Contingent consideration liabilities are measured at their estimated fair value as of the date of acquisition, with subsequent changes in fair value recorded in the consolidated statements of operations. Fair value as of the date of acquisition is estimated based on projections of expected future cash flows of the acquired business. The Company estimated the contingent consideration liability using the income approach (discounted cash flow method) which requires the Company to make estimates and assumptions regarding the future cash flows and profits. Changes in these estimates and assumptions could have a significant impact on the amounts recognized.

There were no transfers between levels in the fair value hierarchy during the three or nine months ended September 30, 2019.

Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

The carrying amounts of cash, accounts receivable, secured revolving credit facility, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments.

The carrying amounts of the secured long-term note payable, equipment financing debt and operating lease liabilities approximate fair value as of September 30, 2019 and December 31, 2018 because those financial instruments bear interest at rates that approximate current market rates for similar agreements with similar maturities and credit.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

See Note 3 – Biocon Acquisition for the allocation of the total consideration for the Biocon Acquisition based upon the fair value of net assets acquired and liabilities assumed at the date of acquisition.

Note 6 – Inventory, net

Inventory is stated at the lower of cost or net realizable value using the first-in, first-out method and consists of raw materials and finished goods. The Company’s inventory components as of September 30, 2019 and December 31, 2018 were as follows:

	September 30, 2019			December 31, 2018
Finished goods		1,849,000		$	1,633,000
Raw materials		354,000			280,000
Less: inventory reserve		(75,000	)		(49,000	)
Total inventory, net	$	2,128,000		$	1,864,000

Note 7 – Intangible Assets and Goodwill

Intangible Assets

The following table shows the gross carrying values and accumulated amortization of the Company’s intangible assets by type as of September 30, 2019:

	September 30, 2019
	Gross Carrying Value		Accumulated Amortization			Intangible Assets, net
Tradenames, service marks and domain names	$	50,000	$	(7,000	)	$	43,000
Customer relationships		540,000		(24,000	)		516,000
Total intangible assets	$	590,000	$	(31,000	)	$	559,000

The Company recognized amortization expense of approximately $10,000 and $31,000 for the three and nine months ended September 30, 2019, respectively in selling, general and administrative expenses on the accompanying condensed consolidated statement of operations and comprehensive loss.

As of September 30, 2019, future amortization expense is estimated to be:

2019 (excluding the nine months ended September 30, 2019)	$	11,000
2020	$	42,000
2021	$	42,000
2022	$	42,000
2023	$	42,000
2024	$	32,000

The Company did not recognize any intangible asset impairment charges during the three or nine months ended September 30, 2019.

Goodwill

Goodwill had a carrying value on the Company’s condensed consolidated balance sheets of approximately $759,000 and $748,000 at September 30, 2019 and December 31, 2018, respectively. As a result of a final working capital adjustment, goodwill increased approximately $11,000 during the nine months ended September 30, 2019. Goodwill has been allocated to the Water Filtration segment.

Note 8 – License and Supply Agreement, net

On April 23, 2012, the Company entered into a License and Supply Agreement (as thereafter amended, the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products, and for an exclusive supply arrangement for the filtration products. Under the License and Supply Agreement Medica granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the filtration products worldwide, with certain limitations on territory, during the term of the License and Supply Agreement. In addition, the Company granted to Medica an exclusive license under the Company’s intellectual property to make the filtration products during the term of the License and Supply Agreement. The filtration products covered under the License and Supply Agreement include both certain products based on Medica’s proprietary Versatile microfiber technology and certain filtration products based on Medica’s proprietary Medisulfone ultrafiltration technology. The term of the License Agreement with Medica expires on December 31, 2025, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement.

In exchange for the license, the gross value of the intangible asset capitalized was approximately $2,250,000. License and supply agreement, net, on the condensed consolidated balance sheet is approximately $837,000 and $938,000 as of September 30, 2019 and December 31, 2018, respectively. Accumulated amortization is approximately $1,413,000 and $1,312,000 as of September 30, 2019 and December 31, 2018, respectively. The intangible asset is being amortized as an expense over the life of the License and Supply Agreement. Amortization expense of approximately $34,000 was recognized in each of the three months ended September 30, 2019 and 2018 on the condensed consolidated statement of operations and comprehensive loss. Amortization expense of approximately $101,000 was recognized in each of the nine months ended September 30, 2019 and 2018 on the condensed consolidated statement of operations and comprehensive loss.

As of September 2013, the Company has an understanding with Medica whereby the Company has agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms. There was no interest recognized for the three or nine months ended September 30, 2019. For the three and nine months ended September 30, 2018, approximately $1,000 and $13,000, respectively, of interest expenses was recognized on the condensed consolidated statement of operations and comprehensive loss.

In addition, for the period beginning April 23, 2014 through December 31, 2025, the Company will pay Medica a royalty rate of 3% of net sales of the filtration products sold, subject to reduction as a result of a supply interruption pursuant to the terms of the License and Supply Agreement. Approximately $82,000 and $48,000 for the three months ended September 30, 2019 and 2018, respectively, was recognized as royalty expense and is included in cost of goods sold on the condensed consolidated statement of operations and comprehensive loss. Approximately $190,000 and $113,000 for the nine months ended September 30, 2019 and 2018, respectively, was recognized as royalty expense and is included in cost of goods sold on the condensed consolidated statement of operations and comprehensive loss. Approximately $82,000 and $50,000 are included in accounts payable as of September 30, 2019 and December 31, 2018, respectively.

Note 9 – Secured Revolving Credit Facility

On August 17, 2017, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Tech Capital, LLC (“Tech Capital”). The Loan Agreement provides for a secured asset-based revolving credit facility of up to $1,000,000, which the Company may draw upon and repay from time to time during the term of the Loan Agreement. The outstanding principal balance of the Loan Agreement was approximately $982,000 and $991,000 as of September 30, 2019 and December 31, 2018, respectively. The Company is using these proceeds for working capital and general corporate purposes.

The Loan Agreement has a term of 12 months, which was automatically renewed on August 17, 2019 and will automatically renew for successive 12-month periods unless cancelled. Availability under the Loan Agreement will be based upon periodic borrowing base certifications valuing certain of the Company’s accounts receivable and inventory. Outstanding borrowings under the Loan Agreement accrue interest, which is payable monthly based on the average daily outstanding balance, at a rate equal to 3.5% plus the prime rate per annum, provided that such prime rate is not less than 4.25% per annum. As of September 30, 2019, the current interest rate was 8.5% per annum.

The Company also granted to Tech Capital a first priority security interest in its assets, including its accounts receivable and inventory, to secure all of its obligations under the Loan Agreement. In addition, Nephros International Limited, the Company’s wholly-owned subsidiary, unconditionally guaranteed the Company’s obligations under the Loan Agreement.

For the three months ended September 30, 2019 and 2018, approximately $17,000 and $9,000, respectively, was recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2019 and 2018, approximately $40,000 and $18,000, respectively, was recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss. As of September 30, 2019, approximately $3,000 of the $40,000 of interest expense incurred for the nine months ended September 30, 2019 is included in accrued expenses on the condensed consolidated balance sheet.

Note 10 – Secured Note Payable

On March 27, 2018, the Company entered into a Secured Promissory Note Agreement (the “Secured Note”) with Tech Capital for a principal amount of $1,187,000. As of September 30, 2019, the principal balance of the Secured Note was approximately $879,000. The Company used the proceeds from the Secured Note to repay the Company’s 11% unsecured promissory notes issued in June 2016 pursuant to the Note and Warrant Agreement (see Note 11 – Unsecured Promissory Notes and Warrants).

The Secured Note has a maturity date of April 1, 2023. The unpaid principal balance accrues interest at a rate of 8% per annum. Principal and interest payments are due on the first day of each month commencing on May 1, 2018. The Secured Note is subject to the terms and conditions of and is secured by security interests granted by the Company in favor of Tech Capital under the Loan Agreement (see Note 9 – Secured Revolving Credit Facility). An event of default under such Loan Agreement will be an event of default under the Secured Note and vice versa. In the event the principal balance under the Loan Agreement is due, all amounts due under the Secured Note will also be due.

During the three and nine months ended September 30, 2019, the Company made payments under the Secured Note of approximately $73,000 and $217,000, respectively. Included in the total payments made, approximately $18,000 and $58,000 was recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2019, respectively. During the three and nine months ended September 30, 2018, the Company made payments under the Secured Note of approximately $72,000 and $144,000, respectively. Included in the total payments made, approximately $22,000 and $45,000, respectively, were recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2018.

Debt issuance costs of approximately $6,000 were recognized as interest expense on the condensed consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2018.

As of September 30, 2019, future principal maturities are as follows:

2019 (excluding the nine months ended September 30, 2019)	$	55,000
2020		231,000
2021		251,000
2022		271,000
2023		71,000
Total	$	879,000

Note 11 - Unsecured Promissory Notes and Warrants

In June 2016, the Company entered into a Note and Warrant Agreement (the “Note and Warrant Agreement”) with new creditors as well as existing stockholders under which the Company issued unsecured promissory notes and warrants resulting in total gross proceeds to the Company of approximately $1,187,000. The outstanding principal under the notes accrued interest at a rate of 11% per annum. The notes required the Company to make interest only payments on a semi-annual basis, with all outstanding principal under the notes being repayable in cash on the third anniversary of the date of issuance. In addition to the notes, the Company issued warrants to purchase approximately 300,000 shares of the Company’s common stock. The portion of the gross proceeds allocated to the warrants, approximately $393,000, was accounted for as additional paid-in capital resulting in a debt discount. The debt discount, which included approximately $9,000 of debt issuance costs in addition to the fair value of the warrants, was being amortized to interest expense using the effective interest method in accordance with ASC 835 over the term of the Note and Warrant Agreement.

On March 30, 2018, the principal balance of the notes, along with the remaining accrued interest of approximately $43,000, was repaid in full. The remaining debt discount of approximately $199,000 was recorded as loss on extinguishment of debt in the Company’s condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2018.

For the nine months ended September 30, 2018, approximately $34,000 was recognized as amortization of debt discount and is included in interest expense on the consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2018, approximately $30,000 of interest expense was incurred.

For the nine months ended September 30, 2018, the amount of interest expense recognized related to related parties comprised of entities controlled by a member of management and by Lambda Investors, LLC, the Company’s largest stockholder, was approximately $1,000.

Note 12 – Leases

The Company has operating leases for corporate offices, an automobile and office equipment. The leases have remaining lease terms of 1 year to 5 years.

The Company entered into an operating lease that began in December 2017 for 380 Lackawanna Place, South Orange, New Jersey 07079, which consists of approximately 7,700 square feet of space. The rental agreement expires in November 2022 with a monthly cost of approximately $11,000. Approximately $11,000 related to a security deposit for this U.S. office facility is classified as other assets on the condensed consolidated balance sheet as of September 30, 2019 and December 31, 2018. The Company uses this facility to house its corporate headquarters and research facilities.

The Company entered into an operating lease that began in February 2019 for 211 Donelson Pike, Nashville, Tennessee 37214, for office space. The rental agreement expires in January 2021 with a monthly cost of approximately $850. Approximately $1,000 related to a security deposit for this office facility is classified as other assets on the condensed consolidated balance sheet as of September 30, 2019.

The Company entered into an operating lease in March 2019 for approximately 16,000 total square feet of office space at 3221 Polaris Avenue, Las Vegas, Nevada 89118. The rental agreement commenced in June 2019 and expires in August 2024 with a monthly cost of approximately $15,000. Approximately $20,000 related to a security deposit for this office facility is classified as other assets on the condensed consolidated balance sheet as of September 30, 2019.

As of August 31, 2019, the Company terminated its rental agreement for 591 East Sunset Road, Henderson, Nevada 89011, which consisted of approximately 8,000 total square feet of space. In connection with the lease termination, the Company and the lessor agreed to a lease termination penalty of $27,000. As of September 30, 2019, the Company recognized a lease termination liability of $20,000, consisting of the $27,000 lease termination penalty offset partially by a security deposit of $7,000. The lease termination liability is included in accrued expenses on the condensed consolidated balance sheet as of September 30, 2019. The $20,000 loss on lease termination in included in selling, general and administrative expenses on the accompanying condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2019.

The lease agreement for the Company’s office space in Ireland was entered into on August 1, 2018 and includes a twelve-month term.

The Company also has lease agreements for an automobile and office equipment.

Prior to the adoption of ASC 842, operating lease expense of approximately $37,000 and $125,000 was recognized in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2018, respectively.

Operating lease expense was approximately $98,000 and $214,000 for the three and nine months ended September 30, 2019, respectively, in the Company’s condensed consolidated statements of operations and comprehensive loss and includes costs associated with leases for which ROU assets have been recognized as well as short-term leases.

Supplemental cash flow information related to leases was as follows:

	Nine months ended September 30, 2019
Operating activities:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	165,000

Noncash investing and financing activities:
ROU assets obtained in exchange for lease obligations
Operating leases	$	800,000

Supplemental balance sheet information related to leases was as follows:

	September 30, 2019

Operating ROU assets	$	1,165,000

Current portion of operating lease liabilities	$	251,000
Operating lease liabilities, net of current portion		956,000
Total operating lease liabilities	$	1,207,000

Weighted average remaining lease term, operating leases		4.2 years

Weighted average discount rate, operating leases		8.0	%

As of September 30, 2019, maturities of lease liabilities were as follows:

2019 (excluding the nine months ended September 30, 2019)	$	84,000
2020		339,000
2021		333,000
2022		329,000
2023		201,000
2024		137,000
Total future minimum lease payments		1,423,000
Less imputed interest		(216,000	)
Total	$	1,207,000

Note 13 – Stock Plans and Share-Based Payments

The fair value of stock options and restricted stock is recognized as stock-based compensation expense in the Company’s condensed consolidated statement of operations and comprehensive loss. The Company and its consolidated subsidiaries calculate stock-based compensation expense in accordance with ASC 718. The fair value of stock-based awards is amortized over the vesting period of the award. The Company’s consolidated subsidiary, SRP, maintains its own equity incentive compensation plan.

Stock Options

During the nine months ended September 30, 2019, the Company granted stock options to purchase 94,806 shares of common stock to employees, directors and a consultant. These stock options are being expensed over the respective vesting period, which is based on a service condition. The fair value of the stock options granted during the nine months ended September 30, 2019 was approximately $398,000.

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model. The below weighted average assumptions for the risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility were utilized for the stock options granted during the nine months ended September 30, 2019.

Weighted Average Assumptions for Option Grants
Stock Price Volatility	90.5	%
Risk-Free Interest Rates	2.1	%
Expected Life (in years)	6.15
Expected Dividend Yield	-	%

During the three and nine months ended September 30, 2019, stock options to purchase 4,166 shares of the Company’s common stock were exercised by a member of management for proceeds of $21,000, resulting in the issuance of 4,166 shares of the Company’s common stock. During the nine months ended September 30, 2018, stock options to purchase 11,111 shares of the Company’s common stock were exercised in a cashless exercise, resulting in the issuance of 2,471 shares of the Company’s common stock.

Stock-based compensation expense related to stock options was approximately $348,000 and $120,000 for the three months ended September 30, 2019 and 2018, respectively. For the three months ended September 30, 2019, approximately $335,000 and $13,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. For the three months ended September 30, 2018, approximately $118,000 and $2,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss.

Stock-based compensation expense related to stock options was approximately $623,000 and $373,000 for the nine months ended September 30, 2019 and 2018, respectively. For the nine months ended September 30, 2019, approximately $577,000 and $46,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2018, approximately $356,000 and $17,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. During the nine months ended September 30, 2018, previously issued stock options were modified for an employee who is no longer employed with the Company. As a result of this modification, included in the approximately $17,000 of research and development expenses is approximately $12,000 of stock option modification expense on the accompanying condensed consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2018.

There was no tax benefit related to expense recognized in the three months ended September 30, 2019 and 2018, as the Company is in a net operating loss position. As of September 30, 2019, there was approximately $966,000 of total unrecognized compensation expense related to unvested stock-based awards granted under the equity compensation plans. Unrecognized compensation expense of approximately $966,000 will be amortized over the weighted average remaining requisite service period of 2.0 years. Such amount does not include the effect of future grants of equity compensation, if any.

Restricted Stock

There was no stock-based compensation expense for restricted stock for the three months ended September 30, 2019 or 2018.

Total stock-based compensation expense for restricted stock was approximately $30,000 and $215,000 for the nine months ended September 30, 2019 and 2018, respectively. For the nine months ended September 30, 2019, approximately $28,000 and $2,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2018, approximately $190,000 and $25,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss.

As of September 30, 2019, all shares of restricted stock have vested.

SRP Equity Incentive Plan

SRP’s 2019 Equity Incentive Plan was approved on May 7, 2019 under which 150,000 shares of SRP’s common stock are reserved for the issuance of options and other awards. During the nine months ended September 30, 2019, SRP granted stock options to purchase 23,040 shares of common stock to its directors and one employee. These stock options are being expensed over the respective vesting period, which is based on a service condition. The fair value of the stock options granted during the nine months ended September 30, 2019 was approximately $88,000.

Weighted Average Assumptions for Option Grants
Stock Price Volatility	92.4	%
Risk-Free Interest Rates	2.3	%
Expected Life (in years)	6.10
Expected Dividend Yield	-	%

Stock-based compensation expense related to the SRP stock options was approximately $6,000 and $9,000 for the three and nine months ended September 30, 2019, respectively. For the three months ended September 30, 2019, approximately $2,000 and $4,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2019, approximately $3,000 and $6,000 are included in selling, general and administrative expenses and research and development expenses, respectively, on the accompanying condensed consolidated statement of operations and comprehensive loss. Stock-based compensation expense related to the SRP stock options is presented by the Company as noncontrolling interest on the condensed consolidated balance sheet as of September 30, 2019.

Note 14 – Stockholders’ Equity

Reverse Stock Split

On July 9, 2019, the Company effected a reverse stock split, in which every nine shares of its common stock issued and outstanding immediately prior to the effective time, which was 5:30 p.m. ET on July 9, 2019, were combined into one share of common stock. Fractional shares were not issued and stockholders who otherwise would have been entitled to receive a fractional share as a result of the reverse stock split received an amount in cash equal to $5.58 per share for such fractional interests. The number of shares of Company common stock issued and outstanding was reduced from approximately 69,000,000 to approximately 7,700,000.

May 2019 Private Placement

On May 15, 2019, the Company entered into a Stock Purchase Agreement with certain accredited investors identified therein pursuant to which the Company issued and sold in a private placement 493,827 shares of the Company’s common stock resulting in gross proceeds to the Company of approximately $2,000,000. The purchase price for each share was $4.05. Proceeds, net of equity issuance costs of $8,000, recorded as a result of the private placement were approximately $1,992,000. Of the 493,827 shares of the Company’s common stock issued, 12,346 shares, resulting in proceeds of approximately $50,000, were sold to a member of management.

April 2018 Private Placement

On April 10, 2018, the Company entered into a Stock Purchase Agreement with certain accredited investors identified therein pursuant to which the Company issued and sold in a private placement 726,735 shares of the Company’s common stock resulting in gross proceeds to the Company of approximately $2,943,000. The purchase price for each share was $4.05. Proceeds, net of equity issuance costs of $19,000, recorded as a result of the private placement were approximately $2,924,000. Of the 726,735 shares of the Company’s common stock issued, 24,331 shares, resulting in proceeds of $98,550, were sold to members of management, including immediate family members.

July 2015 Purchase Agreement and Registration Rights Agreement

On July 24, 2015, the Company entered into both a securities purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the securities purchase agreement, the Company had the right to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $10.0 million in shares of the Company’s common stock, subject to certain limitations, from time to time, over the 36-month period commencing on September 4, 2015. Pursuant to the securities purchase agreement, during the nine months ended September 30, 2018, the Company issued and sold approximately 200,000 shares of its common stock to Lincoln Park. The issuance of the common shares to Lincoln Park resulted in gross proceeds of $854,000 for the nine months ended September 30, 2018. The securities purchase agreement expired on September 4, 2018.

Noncontrolling Interest

On September 5, 2018, SRP entered into a Series A Preferred Stock Purchase Agreement with certain purchasers pursuant to which SRP sold 600,000 shares of its Series A Preferred Stock (“Series A Preferred”) for $5.00 per share, or aggregate gross proceeds of $3,000,000. SRP incurred transaction-related expenses of approximately $30,000, which were included in selling, general and administrative expenses on the accompanying consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2018. The net proceeds from the issuance of the Series A Preferred are restricted to SRP expenses, and may not be used for the benefit of the Company or other affiliated entities, except to reimburse for expenses directly attributable to SRP. Following the Series A Preferred transaction, the Company retained a 62.5% ownership interest in SRP, holding 100% of the outstanding common shares, and holders of Series A Preferred retained a 37.5% interest in SRP on a fully diluted basis, holding 100% of the outstanding preferred shares. Of the 600,000 shares of Series A Preferred issued, the shares purchased by related parties comprised of persons controlled by members of management and by Lambda Investors, LLC, the Company’s largest stockholder, amounted to 18,000 and 400,000 shares, respectively.

Each share of Series A Preferred is initially convertible into one share of SRP common stock, subject to adjustment for stock splits and recapitalization events. Subject to customary exempt issuances, in the event SRP issues additional shares of its common stock or securities convertible into common stock at a per share price that is less than the original Series A Preferred price, the conversion price of the Series A Preferred will automatically be reduced to such lower price.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of SRP, the holders of the Series A Preferred are entitled to be paid out of the assets of SRP available for distribution to its stockholders or, in the case of a deemed liquidation event, out of the consideration payable to stockholders in such deemed liquidation event or the available proceeds, before any payment is made to the holders of SRP common stock by reason of their ownership thereof, an amount per share equal to one times (1x) the Series A Preferred original issue price, plus any accruing dividends accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon (the “Series A Liquidation Preference”). If upon any such liquidation, dissolution or winding up of SRP or deemed liquidation event, the assets of SRP available for distribution to its stockholders are insufficient to pay the Series A Liquidation Preference in full, the holders of Series A Preferred will share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. After the full payment of the Series A Liquidation Preference, the holders of the Series A Preferred and the holders of common stock will share ratably in any remaining proceeds available for distribution on an as-converted to common stock basis.

Each share of Series A Preferred accrues dividends at the rate per annum of $0.40 per share. The accruing dividends accrue from day to day, whether or not declared, and are cumulative and are payable only when, as, and if declared by the Board.

Holders of Series A Preferred are entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A Preferred held by such holder are convertible as of the record date for determining stockholders entitled to vote. Except as provided by law or by the other provisions, the holders of Series A Preferred vote together with the holders of common stock as a single class. Notwithstanding the foregoing, for as long as at least 150,000 shares of Series A Preferred are outstanding, SRP is required to obtain the affirmative vote or written consent of a majority of the Series A Preferred in order to effect certain corporate transactions, including without limitation, the issuance of any securities senior to or on parity with the Series A Preferred, a liquidation or deemed liquidation of SRP, amendments to SRP’s charter documents, the issuance of indebtedness in excess of $250,000, any annual budget for the Company’s operations, and the hiring or firing of any executive officers of SRP. In addition, the holders of the Series A Preferred are entitled to elect two members of SRP’s board of directors.

The noncontrolling interest in SRP held by holders of the Series A Preferred has been classified as equity on the accompanying condensed consolidated balance sheet, as the noncontrolling interest is redeemable only upon the occurrence of events that are within the control of the Company.

Warrants

During the three and nine months ended September 30, 2019, warrants to purchase 108,149 shares of the Company’s common stock were exercised, resulting in proceeds of approximately $292,000 and the issuance of 108,147 shares of the Company’s common stock. Of the warrants exercised during the three and nine months ended September 30, 2019, warrants to purchase 4,444 shares of the Company’s common stock were exercised by members of management, resulting in proceeds of approximately $12,000.

There were no warrant exercises during the three months ended September 30, 2018. During the nine months ended September 30, 2018, warrants to purchase 50,739 shares of the Company’s common stock were exercised, resulting in proceeds of approximately $138,000 and the issuance of 50,739 shares of the Company’s common stock. Of the warrants exercised during the nine months ended September 30, 2018, warrants to purchase 8,147 shares of the Company’s common stock were exercised by members of management, resulting in proceeds of approximately $22,000.

Note 15 – Net Loss per Common Share

Basic loss per common share is calculated by dividing net loss available to common shareholders by the number of weighted average common shares issued and outstanding. Diluted loss per common share is calculated by dividing net loss available to common shareholders by the weighted average number of common shares issued and outstanding for the period, plus amounts representing the dilutive effect from the exercise of stock options and warrants, as applicable. The Company calculates dilutive potential common shares using the treasury stock method, which assumes the Company will use the proceeds from the exercise of stock options and warrants to repurchase shares of common stock to hold in its treasury stock reserves.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive as the Company is in a loss position in all periods presented:

	September 30,
	2019		2018
Shares underlying warrants outstanding		629,921		738,070
Shares underlying options outstanding		887,782		735,509

Note 16 – Commitments and Contingencies

Purchase Commitments

In exchange for the rights granted under the License and Supply Agreement with Medica (see Note 8 – License and Supply Agreement, net), the Company agreed to make certain minimum annual aggregate purchases from Medica over the term of the License and Supply Agreement. For the year ending December 31, 2019, the Company has agreed to make minimum annual aggregate purchases from Medica of €3,000,000 (approximately $3,700,000). As of September 30, 2019, the Company’s aggregate purchase commitments totaled approximately €3,860,000 (approximately $4,320,000).

Contractual Obligations

See Note 12 – Leases for a discussion of the Company’s contractual obligations.

Note 17 – Segment Reporting

During the three months ended September 30, 2018, the Company began reporting the results of SRP as a new segment as a result of the July 2018 formation of the Company’s new subsidiary, SRP. Prior to the formation of SRP, the Company had only a single operating segment. The Company has reflected these new segment measures beginning in the quarter ended September 30, 2018 and prior periods have been restated for comparability.

The Company has defined its two reportable segments as Water Filtration and Renal Products. The Water Filtration segment develops and sells high performance liquid purification filters, known as ultrafilters. The Renal Products segment is focused on the development of medical device products for patients with renal disease, including a 2^nd generation hemodiafiltration system, for the treatment of patients with ESRD.

The Company’s chief operating decision maker evaluates the financial performance of the Company’s segments based upon segment revenues, gross margin and operating expenses which include research and development and selling, general and administrative expenses.

The accounting policies for the Company’s segments are the same as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 with the exception of the adoption of ASC 842 on January 1, 2019.

The tables below present segment information reconciled to total Company loss from operations, with segment operating loss including gross profit less direct research and development expenses and direct selling, general and administrative expenses to the extent specifically identified by segment:

	Three Months Ended September 30, 2019
	Water Filtration			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	3,095,000		$	-		$	3,095,000
Gross margin		1,819,000			-			1,819,000
Research and development expenses		411,000			366,000			777,000
Depreciation and amortization expense		44,000			-			44,000
Selling, general and administrative expenses		1,756,000			31,000			1,787,000
Change in fair value of contingent consideration		(94,000	)		-			(94,000	)
Total operating expenses		2,117,000			397,000			2,514,000
Loss from operations	$	(298,000	)		(397,000	)		(695,000	)

	Nine Months Ended September 30, 2019
	Water Filtration			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	7,173,000			-		$	7,173,000
Gross margin		4,184,000			-			4,184,000
Research and development expenses		1,190,000			1,136,000			2,326,000
Depreciation and amortization expense		142,000			-			142,000
Selling, general and administrative expenses		4,577,000			116,000			4,693,000
Change in fair value of contingent consideration		(113,000	)		-			(113,000	)
Total operating expenses		5,796,000			1,252,000			7,048,000
Loss from operations	$	(1,612,000	)		(1,252,000	)		(2,864,000	)

	Three Months Ended September 30, 2018
	Water Filtration			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	1,724,000		$	-		$	1,724,000
Gross margin		952,000			-			952,000
Research and development expenses		147,000			205,000			352,000
Depreciation and amortization expense		42,000			-			42,000
Selling, general and administrative expenses		970,000			99,000			1,069,000
Total operating expenses		(1,159,000	)		(304,000	)		(1,463,000	)
Loss from operations	$	(207,000	)	$	(304,000	)	$	(511,000	)

	Nine Months Ended September 30, 2018
	Water Filtration			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	4,075,000		$	-		$	4,075,000
Gross margin		2,249,000			-			2,249,000
Research and development expenses		598,000			395,000			993,000
Depreciation and amortization expense		123,000			-			123,000
Selling, general and administrative expenses		3,298,000			122,000			3,420,000
Total operating expenses		(4,019,000	)		(517,000	)		(4,536,000	)
Loss from operations	$	(1,770,000	)	$	(517,000	)	$	(2,287,000	)

As of September 30, 2019, approximately $1,255,000 of total assets are in the Renal Products segment. The $1,255,000 consisted primarily of the remaining cash received of approximately $1,041,000 from the sale of Series A Preferred during the year ended December 31, 2018 and prepaid expenses and other current assets of approximately $200,000.

As of December 31, 2018, approximately $2,500,000 of total assets are in the Renal Products segment. The $2,500,000 consisted of the remaining cash received of approximately $2,300,000 from the sale of Series A Preferred during the year ended December 31, 2018 and prepaid expenses and other current assets of approximately $200,000.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This discussion should be read in conjunction with our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q and the notes thereto, as well as the other sections of this Quarterly Report on Form 10-Q, including the “Forward-Looking Statements” section hereof, and our Annual Report on Form 10-K for the year ended December 31, 2018, including the “Risk Factors” and “Business” sections thereof. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risk factors described in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2018. Our actual results may differ materially.

Business Overview

We are a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets.

In medical device markets, our filters, generally classified as ultrafilters, are used primarily by hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. Because our ultrafilters capture contaminants as small as 0.005 microns in size, they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins.

In commercial markets, we manufacture and sell filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Marketed under both the Nephros and AETHER™ brands, our products are used in the health care, food service, hospitality, and convenience store markets.

Our subsidiary, Specialty Renal Products, Inc. (“SRP”), is a development-stage medical device company, focused primarily on developing hemodiafiltration (“HDF”) technology. SRP is developing a second generation of the OLpūr H2H Hemodiafiltration System, the only U.S. Food and Drug Administration (“FDA”) 510(k)-cleared medical device that enables nephrologists to provide HDF treatment to patients with end stage renal disease (“ESRD”).

On December 31, 2018, we entered into a Membership Interest Purchase Agreement (the “Agreement”) with Biocon1, LLC, a Nevada limited liability company (“Biocon”), Aether Water Systems, LLC, a Nevada limited liability company (“Aether”), and Gregory Lucas, the sole member of each of Biocon and Aether. Pursuant to the terms of the Agreement, we acquired 100% of the outstanding membership interests of each of Biocon and Aether (the “Biocon Acquisition”).

We were founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize an alternative method to hemodialysis. We have extended our filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.

Reverse Stock Split

On July 9, 2019, we effected a reverse stock split, in which every nine shares of our common stock issued and outstanding immediately prior to the effective time, which was 5:30 p.m. ET on July 9, 2019, were combined into one share of common stock. Fractional shares were not issued and stockholders who otherwise would have been entitled to receive a fractional share as a result of the reverse stock split received an amount in cash equal to $5.58 per share for such fractional interests. The number of shares of our common stock issued and outstanding was reduced from approximately 69,000,000 to approximately 7,700,000.

All of the share and per share amounts discussed in this Quarterly Report on Form 10-Q have been adjusted to reflect the effect of this reverse split.

Our Products

Water Filtration Products

We develop and sell liquid filtration products used in both medical and commercial applications, employing multiple filtration technologies.

In medical markets, our primary filtration mechanism is to pass liquids through the pores of polysulfone hollow fiber. Our filters’ pores are significantly smaller than those of competing products, resulting in highly effective elimination of water-borne pathogens, including legionella bacteria (the cause of Legionnaires disease) and viruses, which are not eliminated by most other microbiological filters on the market. Additionally, the fiber structure and pore density in our hollow fiber enables significantly higher flow rates than in other polysulfone hollow fiber.

In commercial markets, with our recent addition of the AETHER product line, carbon-based absorption is the primary filtration mechanism. AETHER products allow us to improve water’s odor and taste, to reduce scale and heavy metals, and to reduce other water contaminants for customers who are primarily in the food service, convenience store, and hospitality industries.

The Biocon business acquisition has the potential to generate accretive revenue growth in at least three potential ways. First, we expect the business to continue its rapid organic growth, which it was experiencing before being acquired. Second, cross-selling opportunities are generated by offering taste/odor-focused products to the medical device markets, as well as pathogen-focused filtration to the commercial markets. Finally, as part of the more substantial Nephros organization, AETHER may be able to compete for larger filtration contracts than may have been available to it as a smaller, independent firm. With nine months of results to date, we have seen some promising results in each of these strategies, but it is still too early to judge the likelihood or magnitude of their long-term success.

Our sales strategy is a combination of direct selling to end customers and indirect selling through value-added resellers (“VARs”). Leveraging VARs has enabled us to expand rapidly our access to target customers in the medical market without significant sales staff expansion. In addition, while we are currently focused in medical markets, the VARs that support these customers also support a wide variety of commercial and industrial customers. We believe that our VAR relationships will facilitate growth in filter sales outside of the medical industry.

Target Markets

Our ultrafiltration products currently target the following markets:

	●	Hospitals and Other Healthcare Facilities: Filtration of water for washing and drinking as an aid in infection control. The filters produce water that is suitable for wound cleansing, cleaning of equipment used in medical procedures, and washing of surgeons’ hands. In addition, we are developing a broad-spectrum diagnostic tool for our hospital and other health care customers to provide them with the ability to assess water safety risks on a real-time basis.
	●	Dialysis Centers: Filtration of water or bicarbonate concentrate used in hemodialysis.
	●	Commercial Facilities: Filtration and purification of water for consumption, including for use in ice machines and soft drink dispensers.
	●	Military and Outdoor Recreation: Individual water purification devices used by soldiers and backpackers to produce drinking water in the field, as well as filters customized to remote water processing systems.

Hospitals and Other Healthcare Facilities. According to the American Hospital Association, approximately 6,200 hospitals, with approximately 931,000 beds, treated over 36 million patients in the United States in 2017. The U.S. Centers for Disease Control and Prevention estimates that healthcare associated infections (“HAI”) occurred in approximately 1 out of every 31 hospital patients, or about 687,000 patients in 2015. HAIs affect patients in hospitals or other healthcare facilities and are not present or incubating at the time of admission. They also include infections acquired by patients in the hospital or facility, but appearing after discharge, and occupational infections among staff. Many HAIs are caused by waterborne bacteria and viruses that can thrive in aging or complex plumbing systems often found in healthcare facilities.

The Affordable Care Act, passed in March 2010, puts in place comprehensive health insurance reforms that aim to lower costs and enhance quality of care. With its implementation, healthcare providers have substantial incentives to deliver better care or be forced to absorb the expenses associated with repeat medical procedures or complications like HAIs. As a consequence, hospitals and other healthcare facilities are proactively implementing strategies to reduce HAI potential. Our ultrafilters are designed to aid in infection control in the hospital and healthcare setting by treating facility water at the points of delivery, such as ice machines, sinks and showers.

In June 2017, the Center for Clinical Standards and Quality at the Centers for Medicare and Medicaid Services (“CMS”) announced the addition of requirements for facilities to develop policies and procedures that inhibit the growth and spread of legionella and other opportunistic pathogens in building water systems. Going forward, CMS surveyors will review policies, procedures, and reports documenting water management implementation results to verify that facilities are compliant with these requirements. We believe that these CMS regulations may have a positive impact on the sale of our HAI-inhibiting ultrafilters.

We currently have FDA 510(k) clearance on the following portfolio of medical device products for use in the hospital setting to aid in infection control:

	●	The DSU-H is an in-line, 0.005-micron ultrafilter that provides dual-stage protection from water borne pathogens. The DSU-H is primarily used to filter potable water feeding ice machines, sinks, and medical equipment, such as endoscope washers and surgical room humidifiers. The DSU-H has an up to 6-month product life when used in a hospital setting.
	●	The SSU-H is an in-line, 0.005-micron ultrafilter that provides single-stage protection from water borne pathogens. The SSU-H is primarily used to filter potable water feeding sinks, showers and medical equipment. The SSU-H has an up to 3-month product life when used in a hospital setting.
	●	The S100 is a point-of-use, 0.01-micron microfilter that provides protection from water borne pathogens. The S100 is primarily used to filter potable water feeding sinks and showers. The S100 has an up to 3-month product life when used in a hospital setting.
	●	The HydraGuard^TM and HydraGuard^TM - Flush are 0.005-micron cartridge ultrafilters that provide single-stage protection from water borne pathogens. The HydraGuard ultrafilters are primarily used to filter potable water feeding ice machines and medical equipment, such as endoscope washers and surgical room humidifiers. The HydraGuard^TM has an up-to 6-month product life and the HydraGuard - Flush has an up to 12-month product life when used in a hospital setting.

We received FDA 510(k) clearance to market the HydraGuard in December 2016 and began shipping it in July 2017. We began shipping the HydraGuard - Flush in September 2017. The DSU-H, SSU-H, and S100 products received FDA 510(k) clearance in prior years.

Our complete hospital infection control product line, including in-line, point-of-use, and cartridge filters, can be viewed on our website athttp://www.nephros.com/infection-control/. We are not including the information on our website as a part of, nor incorporating it by reference into, this Quarterly Report on Form 10-Q.

In addition, we are currently developing a water pathogen detection system designed to enable real-time analysis of water for the presence of borne pathogens, which we expect will complement our medical water filtration products. We plan to offer the system initially to customers and prospective customers that focus on infection control, including hospitals, dialysis centers, and other health care facilities. Following the initial launch, we plan to market the system to other markets as well, including those addressed by our AETHER product lines.

Based on discussions with potential partners and customers, we expect the water pathogen detection system to lead to significantly increased sales, as well as to position ourselves and our strategic distribution partners as strategic partners to our customers in the infection control market, providing pathogen detection expertise as well as filtration products. We expect to launch this system initially as a service in late 2019 and to work with our current strategic distribution partners to roll out the system in 2020.

Dialysis Centers - Water/Bicarbonate. To perform hemodialysis, all dialysis clinics have dedicated water purification systems to produce water and bicarbonate concentrate, two essential ingredients for making dialysate, the liquid that removes waste material from the blood. According to the American Journal of Kidney Diseases, there are approximately 6,500 dialysis clinics in the United States servicing approximately 468,000 patients annually. We estimate that there are over 100,000 hemodialysis machines in operation in the United States.

Medicare is the main payer for dialysis treatment in the United States. To be eligible for Medicare reimbursement, dialysis centers must meet the minimum standards for water and bicarbonate concentrate quality set by the Association for the Advancement of Medical Instrumentation (“AAMI”), the American National Standards Institute (“ANSI”) and the International Standards Organization (“ISO”). We anticipate that the stricter standards approved by these organizations in 2009 will be adopted by Medicare in the near future.

We currently have FDA 510(k) clearance on the following portfolio of medical device products for use in the dialysis setting to aid in bacteria, virus, and endotoxin retention:

	●	The DSU-D, SSU-D and SSUmini are in-line, 0.005-micron ultrafilters that provide protection from bacteria, viruses, and endotoxins. All of these products have an up to 12-month product life in the dialysis setting and are used to filter water following treatment with a reverse osmosis (“RO”) system, and to filter bicarbonate concentrate. These ultrafilters are primarily used in the water lines and bicarbonate concentrate lines leading into dialysis machines, and as a polish filter for portable RO machines.
	●	The EndoPur is a 0.005-micron cartridge ultrafilter that provides single-stage protection from bacteria, viruses, and endotoxins. The EndoPur has an up to 12-month product life in the dialysis setting, and is used to filter water following treatment with an RO system. More specifically, the EndoPur is used primarily to filter water in large RO systems designed to provide ultrapure water to an entire dialysis clinic. The EndoPur is available in 10”, 20”, and 30” configurations.

The EndoPur is a cartridge-based, “plug and play” market entry that requires no plumbing at installation or replacement. In March 2017, we received FDA 510(k) clearance to market the EndoPur filter. We began shipping the EndoPur 10” filter in July 2017 and the 20” and 30” versions in September 2017.

Commercial and Industrial Facilities. Our commercial NanoGuard® product line accomplishes ultrafiltration via small pore size (0.005 micron) technology, filtering bacteria and viruses from water. Our recent acquisition of Biocon and Aether - marketed under the AETHER brand - expands our product line to include additional water filtration and purification technologies, primarily focused on improving odor and taste and on reducing scale and heavy metals from filtered water.

We currently market the following portfolio of proprietary products for use in the commercial, industrial, and food service settings:

	●	The NanoGuard set of products are in-line, 0.005-micron ultrafilter that provides dual-stage retention of any organic or inorganic particle larger than 15,000 Daltons. NanoGuard products are designed to fit a variety of existing plumbing configurations, including 10” and 20” standard housings, and AETHER and Everpure® manifolds. Included in the NanoGuard product line are both conventional and flushable filters.
	●	The AETHER line of commercial filters, which are also sold with under the Nephros brand, provide a variety of technology solutions that improve water quality in food service, convenience store, hospitality, and industrial applications. AETHER filters improve water taste and odor, and reduce sediment, dirt, rust particles and other solids, chlorine and heavy minerals, lime scale build-up, and both particulate lead and soluble lead.

AETHER products combine effectively with NanoGuard ultrafiltration technologies to offer full-featured solutions to the commercial water market, including to existing users of Everpure filter manifolds.

Military and Outdoor Recreation. We developed our individual water treatment device (“IWTD”) in both in-line and point-of-use configurations. Our IWTD allows a soldier in the field to derive drinking water from any freshwater source. This enables the soldier to remain hydrated, to help maintain mission effectiveness and unit readiness, and to extend mission reach. Our IWTD has been validated by the military to meet the NSF Protocol P248 standard. It has also been approved by the U.S. Army Public Health Command and the U.S. Army Test and Evaluation Command for deployment.

In May 2015, we entered into a Sublicense Agreement (the “Sublicense Agreement”) with CamelBak Products, LLC (“CamelBak”). Under this Sublicense Agreement, we granted CamelBak an exclusive, non-transferable, worldwide (with the exception of Italy) sublicense and license, in each case solely to market, sell, distribute, import and export the IWTD. In exchange for the rights granted to CamelBak, CamelBak agreed, through December 31, 2022, to pay us a percentage of the gross profit on any sales made to a branch of the U.S. military, subject to certain exceptions, and to pay us a fixed per-unit fee for any other sales made. CamelBak was also required to meet or exceed certain minimum annual fees payable to us, and, if such fees are not met or exceeded, we may convert the exclusive sublicense to a non-exclusive sublicense with respect to non-U.S. military sales. In the first quarter of 2019, the Sublicense Agreement was amended to eliminate the minimum fee obligations starting May 6, 2018 and, as such, Camelbak has no further minimum fee obligations. CamelBak product sales have been slower than originally hoped. However, military contracts often take years to close, and we remain optimistic about these products and markets.

Specialty Renal Products: HDF System

Introduction to HDF

The current standard of care in the United States for patients with chronic renal failure is hemodialysis (“HD”), a process in which toxins are cleared via diffusion. Patients typically receive HD treatments at least 3 times weekly for 3-4 hours per treatment. HD is most effective in removing smaller, easily diffusible toxins. For patients with acute renal failure, the current standard of care in the United States is hemofiltration (“HF”), a process where toxins are cleared via convection. HF offers a much better removal of larger sized toxins when compared to HD; however, HF treatment is more challenging for patients, as it is performed on a daily basis, and typically takes 12-24 hours per treatment.

Hemodiafiltration (“HDF”) is an alternative dialysis modality that combines the benefits of HD and HF into a single therapy by clearing toxins using both diffusion and convection. Though not widely used in the United States, HDF is prevalent in Europe and is performed for a growing number of patients. Clinical experience and literature show the following clinical and patient benefits of HDF:

	●	Enhanced clearance of middle and large molecular weight toxins
	●	Improved survival - up to a 35% reduction in mortality risk
	●	Reduction in the occurrence of dialysis-related amyloidosis
	●	Reduction in inflammation
	●	Reduction in medication such as EPO and phosphate binders
	●	Improved patient quality of life
	●	Reduction in number of hospitalizations and overall length of stay

However, like HD, HDF can be resource-intensive and can require a significant amount of time to deliver one course of treatment.

Nephros HDF Background

Over the course of our history, we originally developed a medical device that enabled a standard HD machine to perform HDF. We refer to our approach as an on-line mid-dilution hemodiafiltration (“mid-dilution HDF”) system. Our original solution included an OLpūr H2H Hemodiafiltration Module (“H2H Module”), an OLpūr MD 220 Hemodiafilter (“HDF Filter”) and an H2H Substitution Filter (“Dialysate Filter”).

Our H2H Module attaches to a standard HD machine to perform on-line HDF therapy. The HD machine controls and monitors the basic treatment functions, as it would normally when providing HD therapy. The H2H Module is a free-standing, movable device that is placed next to either side of an HD machine. The H2H Module connects to the clinic’s water supply, drain, and electricity.

The H2H Module utilizes the HDF Filter, and is very similar to a typical hollow fiber dialyzer assembled with a single hollow fiber bundle made with a high-flux (or high-permeability) membrane. The fiber bundle is separated into two discrete, but serially connected, blood paths. Dialysate flows in one direction that is counter-current to blood flow in Stage 1 and co-current to blood flow in Stage 2.

In addition to the HDF Filter, the H2H Module also utilizes a Dialysate Filter during patient treatment. The Dialysate Filter is a hollow fiber, ultrafilter device that consists of two sequential (redundant) ultrafiltration stages in a single housing. During on-line HDF with the H2H Module, fresh dialysate is redirected by the H2H Module’s hydraulic (substitution) pump and passed through this dual-stage ultrafilter before being infused as substitution fluid into the extracorporeal circuit. Providing ultrapure dialysate is crucial for the success of on-line HDF treatment.

Our original HDF system conformed with current ANSI/AAMI/ISO standards and was cleared by the FDA for the treatment of patients with chronic renal failure in 2012. To date, our HDF System is the only HDF system cleared by the FDA.

Over the last four years, DaVita Healthcare Partners, the Renal Research Institute (a research division of Fresenius Medical Care), and Vanderbilt University conducted post-market evaluations of our hemodiafiltration system in their clinics. We gathered direct feedback from these evaluations to develop a better understanding of how our system best fits into the current clinical and economic ESRD treatment paradigm. The ultimate goal of the evaluations was to better understand the potential for HDF, in the U.S. clinical setting in order to (a) improve the quality of life for the patient, (b) reduce overall expenditure compared to other dialysis modalities, (c) minimize the impact on nurse work flow at the clinic, and (d) demonstrate the pharmacoeconomic benefit of the HDF technology to the U.S. healthcare system, as has been done in Europe with other HDF systems. The last evaluation was concluded at Vanderbilt in the first quarter of 2018.

Specialty Renal Products, Inc.

Leveraging the results of our evaluations, we recently completed development of a second-generation HDF machine prototype. We believe that the design changes will enable our HDF machine to better align with clinical work-flow practices, to be highly reliable, to simplify the training required for proficiency, and to have a dramatically lower cost of goods. We have filed for patent protection on key features of our updated design.

In July 2018, we formed a new subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of this second-generation HDF system. We intend to fund the HDF program primarily with funds directly raised into SRP, including a $3 million Series A Preferred Stock financing round completed in September 2018. Pending FDA clearance, we believe we can return to the market with our HDF system in the first half of 2020.

Critical Accounting Policies

For the nine month period ended September 30, 2019, other than the adoption of Accounting Standards Codification 842, “Leases” (see Note 2, “Basis of Presentation and Liquidity,” of the Notes to our Unaudited Condensed Consolidated Interim Financial Statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference), there were no significant changes to our critical accounting policies as identified in our Annual Report on Form 10-K for the year ended December 31, 2018.

Recent Accounting Pronouncements

We are subject to recently issued accounting standards, accounting guidance and disclosure requirements. For a description of these new accounting standards, Note 2, “Basis of Presentation and Liquidity,” of the Notes to our Unaudited Condensed Consolidated Interim Financial Statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Results of Operations

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our annual results of operations will be impacted for the foreseeable future by several factors, including the progress and timing of expenditures related to our research and development efforts, marketing expenses related to product launches, timing of regulatory approval of our various products and market acceptance of our products. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance.

The following table sets forth our summarized, consolidated results of operations for the three months ended September 30, 2019 and 2018:

	Three Months Ended September 30,
	2019			2018			$ Increase (Decrease)			% Increase (Decrease)
Total net revenues	$	3,095,000		$	1,724,000		$	1,371,000			80	%
Cost of goods sold		1,276,000			772,000			504,000			65	%
Gross margin		1,819,000			952,000			867,000			91	%
Gross margin %		59	%		55	%		-			4	%
Research and development expenses		777,000			352,000			425,000			121	%
Depreciation and amortization expense		44,000			42,000			2,000			5	%
Selling, general and administrative expenses		1,787,000			1,069,000			718,000			67	%
Change in fair value of contingent consideration		(94,000	)		-			94,000			100	%
Loss from operations		(695,000	)		(511,000	)		184,000			36	%
Interest expense		(48,000	)		(32,000	)		16,000			50	%
Interest income		-			1,000			(1,000	)		(100	)%
Other expense, net		(1,000	)		(8,000	)		(7,000	)		(88	)%
Net loss		(744,000	)		(550,000	)		194,000			35	%
Less: Undeclared deemed dividend attributable to noncontrolling interest		(60,000	)		(16,000	)		44,000			275	%
Net loss attributable to Nephros, Inc.	$	(804,000	)	$	(566,000	)	$	238,000			42	%

Water Filtration

The following table sets forth results of operations for the Water Filtration segment for the three months ended September 30, 2019 and 2018:

	Three Months Ended September 30,
	2019			2018			$ Increase (Decrease)		% Increase (Decrease)
Total net revenues	$	3,095,000		$	1,724,000		$	1,371,000		80	%
Cost of goods sold		1,276,000			772,000			504,000		65	%
Gross margin		1,819,000			952,000			867,000		91	%
Gross margin		59	%		55	%		-		4	%
Research and development expenses		411,000			147,000			264,000		180	%
Depreciation and amortization expense		44,000			42,000			2,000		5	%
Selling, general and administrative expenses		1,756,000			970,000			786,000		81	%
Change in fair value of contingent consideration		(94,000	)		-			94,000		100	%
Loss from operations	$	(298,000	)	$	(207,000	)	$	91,000		44	%

Net Revenues

Total net revenues for the three months ended September 30, 2019 were approximately $3,095,000 compared to approximately $1,724,000 for the three months ended September 30, 2018. The increase of approximately $1,371,000, or 80%, was driven by significant increased medical device sales, to both new and existing customer accounts, as well as our expansion into commercial markets.

Cost of Goods Sold

Cost of goods sold was approximately $1,276,000 for the three months ended September 30, 2019 compared to approximately $772,000 for the three months ended September 30, 2018. The increase of approximately $504,000, or 65%, occurred at a lower rate than the increase to net revenues due to a volume discount from our manufacturer of approximately $67,000. Absent this nonrecurring item, the increase in cost of goods sold would have been approximately $571,000, or 74%, which is consistent with the rate of our revenue increase.

Gross Margin

Gross margin was approximately 59% for the three months ended September 30, 2019 compared to approximately 55% for the three months ended September 30, 2018. The increase of approximately 4% is primarily due to a volume discount from our manufacturer recognized in the three months ended September 30, 2019.

Research and Development Expenses

Research and development expenses were approximately $411,000 and $147,000 for the three months ended September 30, 2019 and 2018, respectively. This increase of approximately $264,000, or 180%, reflects a net increase in expenditures on product development for our new water pathogen detection tool.

Depreciation and Amortization Expense

Depreciation and amortization expenses were approximately $44,000 for the three months ended September 30, 2019 compared to approximately $42,000 for the three months ended September 30, 2018. The increase of approximately $2,000, or 5%, is primarily due to amortization of intangible assets recognized in the Biocon Acquisition.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $1,756,000 for the three months ended September 30, 2019 compared to approximately $970,000 for the three months ended September 30, 2018, representing an increase of $786,000, or 81%. The increase was primarily due to increased headcount-related expenses of approximately $299,000, increased stock based compensation expense of approximately $218,000, primarily related to the vesting of options as a result of the performance condition met upon our recent Nasdaq listing, increased investor relations expenses of approximately $66,000, primarily related to our recent Nasdaq listing, increased other expenses of approximately $145,000, primarily related to rent and warehouse expenses associated with the Las Vegas facility expansion, and increased professional services marketing expenses of approximately $23,000.

Change in Fair Value of Contingent Consideration

Change in fair value of contingent consideration was approximately $94,000 for the three months ended September 30, 2019, due to lower than expected Biocon performance in the three months ended September 30, 2019.

Interest Expense

Interest expense increased approximately $16,000 primarily due to an increase in interest expense related to the secured revolving credit facility of approximately $8,000 during the three months ended September 30, 2019 and accretion expense of approximately $13,000 related to contingent consideration partially offset by a decrease in interest expense of approximately $4,000 related to the secured note payable.

Interest Income

There was no interest income for the three months ended September 30, 2019. Interest income of approximately $1,000 for the three months ended September 30, 2018 was a result of interest income recognized on an equipment lease. This equipment lease was terminated as a result of the Biocon Acquisition on December 31, 2018.

Other Expense

Other expense was approximately $1,000 and $8,000 for the three months ended September 30, 2019 and 2018, respectively, as a result of losses on foreign currency transactions.

Renal Products

The following table sets forth results of operations for the Renal Products segment for the three months ended September 30, 2019 and 2018:

	Three Months Ended September 30,
	2019			2018			$ Increase (Decrease)			% Increase (Decrease)
Research and development expenses	$	366,000		$	205,000		$	161,000			79	%
Selling, general and administrative expenses		31,000			99,000			(68,000	)		(69	)%
Loss from operations	$	(397,000	)	$	(304,000	)	$	93,000			31	%

Research and Development Expenses

Research and development expenses were approximately $366,000 and $205,000 for the three months ended September 30, 2019 and 2018, respectively, an increase of approximately $161,000 due to increased investment in the development of our second-generation HDF product.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $31,000 and $99,000 for the three months ended September 30, 2019 and 2018, respectively, a decrease of approximately $68,000 primarily due to reduced administrative expenses and the absence of legal fees incurred during the three months ended September 30, 2018 as a result of the formation of SRP.

Nine months Ended September 30, 2019 Compared to the Nine months Ended September 30, 2018

The following table sets forth our summarized, consolidated results of operations for the nine months ended September 30, 2019 and 2018:

	Nine months Ended September 30,
	2019			2018			$ Increase (Decrease)			% Increase (Decrease)
Total net revenues	$	7,173,000		$	4,075,000		$	3,098,000			76	%
Cost of goods sold		2,989,000			1,826,000			1,163,000			64	%
Gross margin		4,184,000			2,249,000			1,935,000			86	%
Gross margin		58	%		55	%		-			3	%
Research and development expenses		2,326,000			993,000			1,333,000			134	%
Depreciation and amortization expense		142,000			123,000			19,000			15	%
Selling, general and administrative expenses		4,693,000			3,420,000			1,273,000			37	%
Change in fair value of contingent consideration		(113,000	)		-			113,000			100	%
Loss from operations		(2,864,000	)		(2,287,000	)		577,000			25	%
Loss on extinguishment of debt		-			(199,000	)		(199,000	)		(100	)%
Interest expense		(140,000	)		(146,000	)		(6,000	)		(4	)%
Interest income		-			3,000			(3,000	)		(100	)%
Other expense, net		(31,000	)		(32,000	)		(1,000	)		(3	)%
Net loss		(3,035,000	)		(2,661,000	)		374,000			14	%
Less: Undeclared deemed dividend attributable to noncontrolling interest		(180,000	)		(16,000	)		164,000			1025	%
Net loss attributable to Nephros, Inc.	$	(3,215,000	)	$	(2,677,000	)	$	538,000			20	%

Water Filtration

The following table sets forth results of operations for the Water Filtration segment for the nine months ended September 30, 2019 and 2018:

	Nine months Ended September 30,
	2019			2018			$ Increase (Decrease)			% Increase (Decrease)
Total net revenues	$	7,173,000		$	4,075,000		$	3,098,000			76	%
Cost of goods sold		2,989,000			1,826,000			1,163,000			64	%
Gross margin		4,184,000			2,249,000			1,935,000			86	%
Gross margin		58	%		55	%		-			3	%
Research and development expenses		1,190,000			598,000			592,000			99	%
Depreciation and amortization expense		142,000			123,000			19,000			15	%
Selling, general and administrative expenses		4,577,000			3,298,000			1,279,000			39	%
Change in fair value of contingent consideration		(113,000	)		-			113,000			100	%
Loss from operations	$	(1,612,000	)	$	(1,770,000	)	$	(158,000	)		(9	)%

Net Revenues

Total net revenues for the nine months ended September 30, 2019 were approximately $7,173,000 compared to approximately $4,075,000 for the nine months ended September 30, 2018. The increase of approximately $3,098,000, or 76%, was driven by significant increased medical device sales, to both new and existing customer accounts, as well as our expansion into commercial markets.

Cost of Goods Sold

Cost of goods sold was approximately $2,989,000 for the nine months ended September 30, 2019 compared to approximately $1,826,000 for the nine months ended September 30, 2018. The increase of approximately $1,163,000, or 64%, occurred at a lower rate than the increase to net revenues due to a volume discount from our manufacturer of approximately $67,000 and a decrease in expenses related to inventory adjustments and reserves for expiring items of approximately $92,000. Absent these nonrecurring items, the increase in cost of goods sold would have been approximately $1,322,000, or 76%, which is consistent with the rate of our revenue increase.

Gross Margin

Gross margin was approximately 58% for the nine months ended September 30, 2019 compared to approximately 55% for the nine months ended September 30, 2018. The increase of approximately 3% is primarily due to a volume discount from our manufacturer and a decrease in inventory adjustments and reserves for expiring items.

Research and Development Expenses

Research and development expenses were approximately $1,190,000 and $598,000 for the nine months ended September 30, 2019 and 2018, respectively. This increase of approximately $592,000, or 99%, reflects an increase in R&D headcount plus expenditures on product development for our new water pathogen detection tool.

Depreciation and Amortization Expense

Depreciation and amortization expenses were approximately $142,000 for the nine months ended September 30, 2019 compared to approximately $123,000 for the nine months ended September 30, 2018. The increase of approximately $19,000, or 15%, is due to amortization of intangible assets recognized in the Biocon Acquisition.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $4,577,000 for the nine months ended September 30, 2019 compared to approximately $3,298,000 for the nine months ended September 30, 2018, representing an increase of $1,279,000, or 39%. The increase was primarily due to increased headcount-related expenses of approximately $606,000, increased stock based compensation expense of approximately $63,000 , increased professional services marketing expenses of approximately $236,000, increased investor relations expenses of approximately $84,000, primarily related to our recent Nasdaq listing, and increased other expenses of approximately $216,000, primarily related to rent and warehouse expenses associated with Las Vegas and New Jersey facility expansions.

Change in Fair Value of Contingent Consideration

Change in fair value of contingent consideration was approximately $113,000 for the nine months ended September 30, 2019, due to lower than expected Biocon performance in the three months ended September 30, 2019.

Interest Expense

Interest expense decreased approximately $6,000 primarily due to interest and the related debt discount on the unsecured long-term note payable of approximately $64,000 that was paid off during the nine months ended September 30, 2018 and a decrease in interest paid to a vendor of approximately $12,000 offset partially by an increase of approximately $29,000 on interest expense on the secured note payable and the secured revolving credit facility during the nine months ended September 30, 2019 and an increase in accretion expense of approximately $41,000 related to contingent consideration during the nine months ended September 30, 2019.

Interest Income

There was no interest income for the nine months ended September 30, 2019. Interest income of approximately $3,000 for the nine months ended September 30, 2018 was a result of interest income recognized on an equipment lease. This equipment lease was terminated as a result of the Biocon Acquisition on December 31, 2018.

Other Expense

Other expense was approximately $31,000 and $32,000 for the nine months ended September 30, 2019 and 2018, respectively. Other expense for the nine months ended September 30, 2019 includes approximately $36,000 related to foreign currency transaction losses partially offset by other income of approximately $5,000. Other expense for the nine months ended September 30, 2018 is a result of losses on foreign currency transactions.

Renal Products

The following table sets forth results of operations for the Renal Products segment for the nine months ended September 30, 2019 and 2018:

	Nine months Ended September 30,
	2019			2018			$ Increase (Decrease)			% Increase (Decrease)
Research and development expenses	$	1,136,000		$	395,000		$	741,000			188	%
Selling, general and administrative expenses		116,000			122,000			(6,000	)		(5	)%
Loss from operations	$	(1,252,000	)	$	(517,000	)	$	735,000			142	%

Research and Development Expenses

Research and development expenses were approximately $1,136,000 and $395,000 for the nine months ended September 30, 2019 and 2018, respectively, an increase of approximately $741,000 due to increased investment in the development of our second-generation HDF product.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $116,000 and $122,000 for the nine months ended September 30, 2019 and 2018, respectively, a decrease of approximately $6,000, primarily due to reduced administrative expenses and the absence of legal fees incurred during the three months ended September 30, 2018 as a result of the formation of SRP, partially offset by an increased investment in the development of our second-generation HDF product.

Liquidity and Capital Resources

The following table summarizes our liquidity and capital resources as of September 30, 2019 and December 31, 2018 and is intended to supplement the more detailed discussion that follows. The amounts stated are expressed in thousands.

Liquidity and Capital Resources	September 30, 2019		December 31, 2018
Cash	$	3,855	$	4,581
Other current assets		4,262		3,592
Working capital		5,001		5,519
Stockholders’ equity		6,722		6,798

At September 30, 2019, we had an accumulated deficit of approximately $127,188,000 and we expect to incur additional operating losses from operations until such time, if ever, that we are able to increase product sales and/or licensing revenue to achieve profitability.

Our cash flow from operations currently is not, and historically has not been, sufficient to meet our obligations and commitments. Based on cash that is available for our operations and projections of our future operations, we believe that our cash will be sufficient to fund our current operating plan through at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. In the event that operations do not meet expectations, we will reduce discretionary expenditures such as additional headcount, new R&D projects, and other variable costs to alleviate the substantial doubt as to our ability to continue as a going concern. We may also seek to raise additional capital, however, there can be no assurance that any such actions could be affected on a timely basis or on satisfactory terms or at all, or that these actions would enable us to continue to satisfy our capital requirements.

Our future liquidity sources and requirements will depend on many factors, including:

	●	the market acceptance of our products and our ability to effectively and efficiently produce and market our products;
	●	the continued progress in, and the costs of, clinical studies and other research and development programs;
	●	the costs involved in filing and enforcing patent claims and the status of competitive products; and
	●	the cost of litigation, including potential patent litigation and any other actual or threatened litigation.

We expect to put our current capital resources to the following uses:

	●	the development, marketing, and sales of our water-filtration and water diagnostics products;
	●	the development of our second-generation HDF product; and
	●	working capital purposes.

At September 30, 2019, we had cash totaling approximately $3,855,000 and total assets of approximately $10,717,000, excluding other intangible assets (related to the License and Supply Agreement with Medica) of approximately $837,000.

Net cash used in operating activities was approximately $2,640,000 for the nine months ended September 30, 2019 compared to approximately $3,134,000 for the nine months ended September 30, 2018, an decrease of approximately $494,000. This decrease is due to a combination of factors, primarily lower expenditures on inventory as a result of managing inventory levels and improvements in gross margins partially offset by increased research and development expenses.

Net cash used in investing activities was approximately $151,000 for the nine months ended September 30, 2019 due to a working capital adjustment related to the Biocon Acquisition and an equipment purchase. There was no cash used in investing activities for the nine months ended September 30, 2018.

Net cash provided by financing activities of approximately $2,072,000 for the nine months ended September 30, 2019 resulted from net proceeds from the issuance of common stock of approximately $1,992,000, proceeds from the exercise of warrants of approximately $292,000, proceeds from the exercise of stock options of approximately $21,000, proceeds from equipment financing of approximately $14,000, partially offset by payments on our secured note payable of approximately $159,000, payment of contingent consideration related to the Biocon Acquisition of approximately $78,000, net payments on our secured revolving credit facility of approximately $9,000 and payments on a financing obligation of approximately $1,000.

Net cash provided by financing activities of approximately $6,269,000 for the nine months ended September 30, 2018 resulted from net proceeds from the issuance of our common stock of approximately $3,778,000, contributions from the sale of preferred stock of SRP to a noncontrolling interest of approximately $3,000,000, proceeds from the issuance of a secured note payable of approximately $1,187,000 and proceeds from the exercise of warrants of approximately $138,000, offset partially by net payments on our secured revolving credit facility of approximately $548,000, payments on our secured note payable of approximately $99,000 and payments on our unsecured long-term note payable of approximately $1,187,000.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2019.

Forward-Looking Statements

Certain statements in this Quarterly Report on Form 10-Q constitute “forward-looking statements” as defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines and strategy for bringing such products to market, the timeline for regulatory review and approval of our products, the availability of funding sources for continued development of such products, and other statements that are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or the negative thereof or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include, but are not limited to, the risks that:

	●	we face significant challenges in obtaining market acceptance of our products, which could adversely affect our potential sales and revenues;
	●	product-related deaths or serious injuries or product malfunctions could trigger recalls, class action lawsuits and other events that could cause us to incur expenses and may also limit our ability to generate revenues from such products;
	●	we face potential liability associated with the production, marketing and sale of our products, and the expense of defending against claims of product liability could materially deplete our assets and generate negative publicity, which could impair our reputation;
	●	to the extent our products or marketing materials are found to violate any provisions of the U.S. Food, Drug and Cosmetic Act or any other statutes or regulations, we could be subject to enforcement actions by the FDA or other governmental agencies;
	●	we may not be able to obtain funding if and when needed or on terms favorable to us in order to continue operations;
	●	we may not have sufficient capital to successfully implement our business plan;
	●	we may not be able to effectively market our products;
	●	we may not be able to sell our water filtration products or chronic renal failure therapy products at competitive prices or profitably;
	●	we may encounter problems with our suppliers, manufacturers and distributors;
	●	we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
	●	we may not obtain appropriate or necessary regulatory approvals to achieve our business plan;
	●	products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
	●	we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
	●	we may not be able to achieve sales growth in key geographic markets.

More detailed information about us and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Quarterly Report on Form 10-Q, is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. We urge investors and security holders to read those documents free of charge at the SEC’s web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not required for smaller reporting companies.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain a system of disclosure controls and procedures, as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is designed to provide reasonable assurance that information required to be disclosed in our reports filed pursuant to the Exchange Act is accumulated and communicated to management in a timely manner. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been or will be detected.

At the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 6. Exhibits

EXHIBIT INDEX

Exhibit No.		Description of Exhibit
31.1		Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
31.2		Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
32.1		Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **
32.2		Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **
101		Interactive Data File. *

*		Filed herewith
**		Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NEPHROS, INC.

Date: November 6, 2019	By:	/s/ Daron Evans
	Name:	Daron Evans
	Title:	President, Chief Executive Officer (Principal Executive
		Officer)

Date: November 6, 2019	By:	/s/ Andrew Astor
	Name:	Andrew Astor
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

Nephros (NEPH) 10-Q2019 Q3 Quarterly report

Content analysis